 |
Journal articles
Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
Abstract : An intercellular spreading strategy using herpes simplex virus type 1 (HSV-1) VP22 protein is employed to enhance DNA vaccine potency of Leishmania major amastin antigen in BALB/c mice model. We evaluated the immunogenicity and protective efficacy of plasmid DNA vaccines encoding amastin-enhanced green fluorescent protein (EGFP) and VP22-amastin-EGFP. Optimal cell-mediated immune responses were observed in BALB/c mice immunized with VP22-amastin-EGFP as assessed by cytokine gene expression analysis using real time RT-PCR. Vaccination with the VP22-amastin-EGFP fusion construct elicited significantly higher IFN-gamma response upon antigen stimulation of splenocytes from immunized mice compared to amastin as a sole antigen. Mice immunized by VP22-amastin-EGFP showed partial protection following infectious challenge with L. major, as measured by parasite load in spleens. These results suggest that the development of DNA vaccines encoding VP22 fused to a target Leishmania antigen would be a promising strategy to improve immunogenicity and DNA vaccine potency.
https://hal-riip.archives-ouvertes.fr/pasteur-00786634
Contributor : Sima Rafati Connect in order to contact the contributor
Submitted on : Saturday, February 9, 2013 - 1:25:03 PM
Last modification on : Wednesday, September 23, 2020 - 10:48:02 AM
Contributor : Sima Rafati Connect in order to contact the contributor
Submitted on : Saturday, February 9, 2013 - 1:25:03 PM
Last modification on : Wednesday, September 23, 2020 - 10:48:02 AM